David J. Fitzgerald
Senior Investigator
Center for Cancer Research
National Cancer Institute
United States of America
Biography
Dr. Fitzgerald is chief of the Biotherapy Section, Laboratory of Molecular Biology, in the NCI. He received his Ph.D. in 1982 from the University of Cincinnati Medical School, Department of Microbiology. The focus of his Ph.D. dissertation was the endocytic uptake of Pseudomonas exotoxin. He has a longstanding interest in bacterial toxins and their use as therapeutic agents.
Research Interest
antibodies, toxins, cancer therapeutics, cell biology, immunotoxins
Publications
-
Mansfield E, Amlot P, Pastan I, FitzGerald DJ. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997 Sep 1;90(5):2020-6.
-
FitzGerald DJ, Fryling CM, Zdanovsky A, Saelinger CB, Kounnas M, Winkles JA, Strickland D, Leppla S. Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein. The Journal of Cell Biology. 1995 Jun 15;129(6):1533-41.
-
Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. Journal of Biological Chemistry. 1990 Nov 25;265(33):20678-85.
